Key result
Genomic research and post-Human Genome Project technologies have identified new predisposition markers to tailor preventive and therapeutic strategies for cardiovascular disease.
Genomic research provides insights into cardiovascular disease mechanisms and holds promise for personalized medicine through tailored preventive and therapeutic strategies.
Answers are grounded in this paper and cite their sources.
May inform future risk stratification; leaves open prospective validation before clinical adoption.
As the leading cause of death worldwide and a major cause of disability, cardiovascular disease remains a central focus of basic research, pharmacological treatment, surgical interventions, and long-term care. Inherited, monogenic syndromes have provided insight into pathophysiological mechanisms across the range of cardiovascular diseases. With the advent of post-Human Genome Project resources and technology, there has been a flood of research aimed at genome-wide predisposition markers, pharmacogenetics, and genomic signatures in complex cardiovascular disorders. Genomic research has both further elucidated the impact of genes previously identified in cardiovascular disease development and progression and discovered genomic regions as yet unknown to be associated with cardiovascular outcomes. The promise of personalized medicine lies in combining this genetic information with other biomarkers to tailor preventive and therapeutic strategies to individual patients for effective management, fewer adverse events, and preventive care.
No takes yet. Share an insight, caveat, or question.
Manace et al. (2009) conducted a review in Cardiovascular disease. Genomic research and post-Human Genome Project technologies have identified new predisposition markers to tailor preventive and therapeutic strategies for cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: